A Protocol for Collecting Human Cardiac Tissue for Research by Blair, Cheavar A et al.
 
 
 
 
The VAD Journal: http://dx.doi.org/10.13023/VAD.2016.12 Page 1 of 13 
 
The VAD Journal: The journal of mechanical assisted circulation and heart failure 
Peer-Reviewed Original Research 
 
A Protocol for Collecting Human 
Cardiac Tissue for Research 
Cheavar A. Blair1, Premi Haynes9, Stuart G. Campbell2, Charles Chung3, 
Mihail I. Mitov8, Donna Dennis4, Mark R. Bonnell6, Charles W. Hoopes7, 
Maya Guglin4,5, Kenneth S. Campbell1,5* 
1 Department of Physiology, University of Kentucky, Lexington, KY 
2 Department of Biomedical Engineering, Yale University, New Haven, CT  
3 Department of Physiology, Wayne State University, Detroit, MI  
4 Gill Heart Institute, University of Kentucky, Lexington, KY  
5 Division of Cardiovascular Medicine, University of Kentucky, Lexington, KY 
6 University of Toledo Medical Center, Toledo, OH 
7 University of Alabama Birmingham School of Medicine, Birmingham, AL 
8 Markey Cancer Center, University of Kentucky, Lexington, KY 
9 Department of Pediatrics, Institute for Stem Cell & Regenerative Medicine, 
University of Washington, Seattle, WA 
* Corresponding author: k.s.campbell@uky.edu 
Abstract 
This manuscript describes a protocol at the University of Kentucky that allows a 
translational research team to collect human myocardium that can be used for 
biological research. We have gained a great deal of practical experience since 
we started this protocol in 2008, and we hope that other groups might be able to 
learn from our endeavors. To date, we have procured ~4000 samples from ~230 
patients. The tissue that we collect comes from organ donors and from patients 
who are receiving a heart transplant or a ventricular assist device because they 
have heart failure. We begin our manuscript by describing the importance of 
human samples in cardiac research. Subsequently, we describe the process for 
obtaining consent from patients, the cost of running the protocol, and some of the 
issues and practical difficulties that we have encountered. We conclude with 
some suggestions for other researchers who may be considering starting a 
similar protocol. 
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Introduction 
 
Heart failure is a clinical syndrome that manifests when there are structural and 
functional impairments to the heart that alters its ability to pump (1). The etiology 
of heart failure is complex but individuals who suffer from cardiovascular 
diseases including cardiomyopathy, myocarditis, hypertension, coronary 
atherosclerosis, and valvular and congenital heart malformations, are at 
increased risk (2). Currently, more than 23 million people worldwide suffer from 
the disease, which has a mortality rate of ~50% within the first five years of 
diagnosis (3). In the United States alone, heart failure affects ~6 million 
individuals with an estimated 650,000 new cases diagnosed annually. Taken 
together, heart failure costs the US healthcare system ~40 billion dollars a year 
(1, 4-6). 
 
Despite intensive efforts, treatment options for patients who have advanced heart 
failure remain limited. Research that identifies mechanisms that contribute to 
impaired ventricular function can offer new hope to patients by supporting the 
development of better therapies. Many significant insights have been obtained to 
date by studying mice and rats. However, there are significant differences 
between the cardiac biology of rodents and humans, including (but not limited to) 
heart rate, oxygen consumption, and adrenergic receptor ratios (7, 8). Large 
animal models, such as dogs, pigs, and sheep, more closely approximate human 
cardiac function but also have limitations. For example, very few academic labs 
can afford to maintain dogs and pigs for research. 
The aim of this manuscript is to describe a collection protocol that we have 
developed at the University of Kentucky to study cardiac samples from patients 
who are suffering from heart failure and research donors with non-failing hearts. 
It has taken us several years to develop and refine this protocol, and we would 
like to share what we have learned with the research community. We hope that 
reading about our experience will encourage other groups to start similar 
collection protocols. Human biospecimens cannot fully replace animal models in 
cardiovascular research. However, we think that many groups might be able to 
use human samples to accelerate their research and increase the translational 
significance of their work. 
Informed Consent 
Our program is approved by the University of Kentucky’s Institutional Review 
Board (IRB) and is an opt-in consent program focusing on advanced heat failure. 
We aim to approach all patients who have been listed for heart transplant or will 
be implanted with a Ventricular Assist Device (VAD) and ask for their consent to 
use samples of their tissue for research. All of the samples that we procure are 
removed as part of normal clinical care and would be discarded if they were not 
saved for research. We do not currently perform pediatric heart transplants or 
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implant VADs into children at the University of Kentucky so all of our patients are 
18 years or older. 
Consents are normally obtained by a member of the patient’s clinical team. We 
have found that it is simplest to obtain consent for potential heart transplant 
patients when they are being listed for transplant. Patients who will be receiving 
VADs are typically consented for research when they are being consented for the 
VAD implant. We explain that the samples we hope to procure will be discarded if 
they are not used for research and describe the potential risks of joining the 
study, which mainly relate to a potential loss of confidentiality if data are 
accidentally disclosed. We have sought consent from hundreds of patients since 
2008 and virtually all of them have agreed to participate. Many of them are 
surprised that this sort of research is not more common. Patients often tell their 
team that they want to support the research because it might prevent somebody 
else from having to experience similar clinical problems. 
Our protocol also allows us to collect myocardial samples from organ donors 
when the heart will not be used for transplant. For example, we might be able to 
acquire hearts that come from donors who have hepatitis or atherosclerosis. At 
the University of Kentucky, researchers and heart failure clinicians do not 
typically interact with the families of organ donors. Instead, the consent to donate 
samples is obtained by a member of the Organ Procurement Organization 
(OPO). Our OPO is Kentucky Organ Donor Affiliates (KODA) who typically ask 
the family of the donor for permission to (a) use organs for transplant, and (b) 
use organs for research if they cannot be used for transplant. If the family of the 
donor agrees to both of these requests, the OPO passes that information on to a 
member of our research team. 
The protocol also allows us to extract data from the medical records of the 
patients who donated samples. We can use these data to link our research 
findings to specific medical conditions. We updated our protocol in 2013 so that 
we could share samples and the associated de-identified medical data (for 
example, age, diagnosis, body mass index, ejection fraction, diabetic status, etc.) 
with researchers at other institutions. This increases the impact of our work and 
further accelerates the research. 
It is important to note that only researchers who are listed on the IRB protocol at 
the University of Kentucky are able to link specimens to specific people. 
Scientists at other institutions are never given access to the 18 types of data that 
are defined as Protected Health Information (PHI) by the Health Insurance 
Portability and Accountability Act (HIPAA). These data fields include names, 
addresses, and medical record numbers that are linked to a specific person. 
At the moment, we have chosen not to return specific research results to the 
patients who donated samples. We explain this when we seek consent and we 
have adopted this approach because our current experiments won’t impact the 
immediate treatment plan. Returning every experimental result to each patient 
might increase anxiety without having a positive effect. We recognize that this is 
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a complex area and might choose to revise the policy in the future as guidelines 
evolve. 
Timeline for tissue procurement 
Our procurement protocol is design to optimize the quality of the samples that we 
collect for research. The main goals are (a) to keep the heart or tissue samples 
cold as soon as they are removed from the patient or organ donor, and (b) to 
minimize the time before the samples are used for experiments with living cells or 
frozen in liquid nitrogen. Typically, samples that are frozen are placed in 
cryogenic vials and dropped into liquid nitrogen within ~30 minutes of being 
removed from the patient. Our experimental data show that this interval is short 
enough to preserve the integrity of sarcomeric proteins and mRNA (9). 
As shown in Fig.1, the timeline for procurement starts when the circulating nurse 
who will be managing the operating room during the cardiac procedure calls a 
dedicated mobile phone. (Scientists in our lab take turns carrying this phone, 
which is answered 24 hours per day.) This first call typically occurs 2 to 3 hours 
before samples will become available so the scientist has time to travel to the 
university if they are not already there, and to prepare their equipment. 
The circulating nurse calls the mobile phone a second time when the surgeon 
makes the first incision. This is the signal for the scientist to leave the lab and to 
walk to the clinical area. After changing into surgical scrubs, the scientist enters 
the operating room and notifies the circulating nurse that they are available to 
receive samples. If the operating room is very busy, the scientist may choose to 
wait outside. Typically though, the scientist waits in the back of the operating 
room for 5 to 60 minutes until the tissue is excised. The surgeon or scrub nurse 
hands the relevant samples to the circulating nurse who passes the tissue 
directly to the scientist. The scientist immediately places the tissue in a plastic 
container filled with cold saline slush, and then inserts that container into an 
insulated box. He/she then carries the insulated box back to the research lab (3 
to 5 minute walk). 
 
Fig. 1. Timeline for tissue procurement 
Once back in the lab, the scientist removes the cardiac tissue from the insulated 
box and begins to dissect the samples. If they are going to attempt experiments 
with living cells, the scientist may isolate trabeculae or through-wall ventricular 
wedge sections. However, the main goal is to freeze samples for subsequent 
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analysis. As shown in Table 1, we aim to isolate sections from three transmural 
regions (sub-endocardial, mid-myocardial, and sub-epicardial) of tissue cores 
procured during VAD implants and from the left ventricular wall of explanted 
hearts. When possible, we also try to produce additional samples from the 
septum, the right ventricle, and both atria. 
Tissue samples are cut into small blocks weighing 500 to 1000 mg and placed 
into pre-labeled 2 ml cryogenic tubes. These are then dropped into liquid nitrogen 
where the tissue freezes rapidly. After all of the samples have been frozen, they 
are placed in freezer boxes, and transferred to large tanks where they are 
maintained in the vapor phase of liquid nitrogen for long-term storage. 
Table 1. Procurement procedure for heart transplant and LVAD samples 
 Heart Transplant LVAD 
Location of 
samples 
collected 
 Left ventricular free wall 
 Right ventricular free wall 
 Atria 
 Septum 
 Through-wall core removed 
from the left ventricular 
apex before the VAD is 
implanted 
Processing  Cut tissue samples that 
are ~5 x 5 cm 
 Split left ventricular 
samples into sub-
endocardial, mid-
myocardial, and sub-
epicardial regions (Fig. 2a) 
 Obtain 6 to 10 samples 
(each 500~1000 mg) for 
each region and place in 
cryogenic vials 
 Split core into transmural 
regions if possible 
 Further dissect into a few (1 
to 3) samples (each ~500 
mg) and place in cryogenic 
vials 
Storage of 
samples 
 Flash freeze samples in liquid nitrogen 
 Place frozen samples in storage box (Fig. 2b) 
 Place box in cryogenic tank for storage in the vapor phase of 
liquid nitrogen (Fig. 2c) 
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Data management 
De-identification 
Only scientists and clinicians who are listed on our IRB protocol are allowed to 
know the identities of the people who donated cardiac tissue. To preserve 
privacy, we therefore allocate a unique randomized identifier (which we term a 
hashcode) to each tissue procurement procedure. The vials containing the tissue 
samples are only labeled with this hashcode and the region of the heart that the 
sample was procured from. This allows us to share samples with other 
researchers without compromising the identity of the patient or donor. 
 
Fig. 2. Tissue dissection and storage.  
Fig. 2a. ~5 cm x 5 cm piece of tissue from the LV annotated to show how 
the samples are separated into three transmural regions.  
Fig. 2b. Storage vials with hashcode and storage box.  
Fig. 2c. Cryogenic tanks that store samples in the vapor phase of liquid 
nitrogen 
Each hashcode consists of 5 characters which are either digits (0 to 9) or letters 
in the range A to F (for example, 34F2A). We generated ~1,000,000 such codes 
at the beginning of our study by creating a random permutation of the integers 
from 1 to 216 and then converting that list to hexadecimal. Hashcodes are 
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selected from the random list in turn so there is no practical way for an outside 
party to link the hashcode to a specific person, or even to an approximate 
procurement date. 
Inventory 
As described, sample vials are labeled only with the hashcode for the 
procurement and the region of the heart that the tissue was acquired from (for 
example, A231E, Right Ventricle). Vials are placed in storage boxes that have 81 
positions (labeled from A1 to I9). These boxes are in turn placed in one of 144 
slots in our 3 cryogenic storage tanks (Fig. 2c). 
We record the hashcode, cardiac region, box position, slot number, and sample 
status (for example, available, or previously thawed) for each sample in Excel 
and use the resulting computer file to manage our inventory. We have several 
computer programs (written in MATLAB) that allow us to select samples and/or 
generate reports from the Excel file. 
Clinical data 
We use REDCap (Research Electronic Data Capture) software (10-13) to store 
and manage the clinical data that we collect for each patient and organ donor. 
This software is a secure, web-based database that is HIPAA compliant and 
approved by our IRB. One of the advantages of REDCap is that it allows us to 
restrict access to patient identifiers. Thus researchers who are not listed on our 
IRB can access the database to download clinical data but cannot obtain 
information about the identity of the patient or donor. This simplifies our logistics 
and makes it easier to manage our protocol. 
Experimental techniques 
We use the myocardial samples that we acquire to investigate cellular and 
molecular mechanisms that contribute to heart failure. We can perform 
experiments immediately after we procure the samples (fresh tissue) or using 
samples that have been previously frozen. Our laboratory specializes in 
experiments assessing contractile properties but we have also analyzed the 
samples using numerous histological and biochemical techniques. 
The techniques that we have implemented using human samples include: 
Fresh tissue:  
 Mechanical studies 
o Single cells –ventricular myocytes are loaded with Fura-2 (a dye 
that indicates the intracellular Ca2+ concentration) and electrically 
stimulated. We use a photomultiplier and a high-speed camera to 
measure the Ca2+ transients and shortening profiles as the cells 
undergo unloaded twitch contractions. 
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o Trabeculae – intact trabeculae are attached between a force 
transducer and motor. We measure contractile force during 
electrically evoked twitch contractions and a range of parameters 
relating to myocardial relaxation.  
Frozen tissue: 
 Mechanical studies 
o Permeabilized single cells – single cells are chemically 
permeabilized using triton and attached between a force 
transducer and a motor. We typically measure contractile force, 
calcium sensitivity (pCa50), and the rate of tension recovery (ktr) at 
different levels of Ca2+ activation. These cells do not have large 
amounts of extracellular matrix so their passive stiffness is 
primarily due to titin molecules. 
o Permeabilized multicellular preparations – larger preparations 
(typically ~600 x 120 x 120 µm) are chemically permeabilized and 
attached between a force transducer and a motor and analyzed 
using similar techniques to those described for single 
permeabilized cells above. The passive stiffness of these 
preparations reflects titin molecules and an additional contribution 
from extracellular matrix proteins. 
 Histology 
 Microarrays to measure mRNA and microRNA levels 
 Gel electrophoresis 
 Collagen analysis 
 PCR 
Personnel and financial costs 
Some of the clinical staff take on additional responsibilities to help us procure 
cardiac samples for research. We list some of these responsibilities along with an 
estimate of the time involved in Table 2. Table 3 shows the responsibilities and 
time commitment for research staff. Finally, Table 4 provides estimates of the 
financial costs. We are providing these data because we think that they may be 
useful to readers who are interested in starting their own procurement system. 
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Table 2 - Clinical staff 
Title Number of 
personnel 
involved 
Responsibilities for this 
program 
Time 
Transplant 
surgeons 
4 Agree to allow samples to 
be used for research 
Minimal 
Transplant 
and VAD 
coordinators 
3 Obtain patient consents 20 minutes per 
patient 
Operating 
room 
nursing staff 
Many Call research scientist, 
hand excised heart to 
scientist 
10 minutes per 
procurement 
Table 3 - Research staff 
Title Number of 
personnel 
involved 
Responsibilities Time 
Scientists 3 Procure samples Up to 4 hours waiting per 
heart plus ~1 hour to 
isolate samples, clean 
the procedure areas, and 
restock supplies. 
IRB manager 1 Maintain IRB protocol, 
manage changes in 
personnel 
20 hours per year 
Clinical data 
manager 
1 Maintain clinical 
database, extract data 
from medical records 
40 hours per year plus 2 
hours per patient 
Sample 
management 
1 Manage specimen 
inventory, maintain 
cryogenic tanks 
6 hours per week 
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Table 4 – Cost 
 
Problems and weaknesses 
One of the challenges that we have faced with this protocol is ensuring that 
scientists are available 24/7 to collect the samples from the operating room. This 
is a particular problem for heart transplants because these procedures can occur 
at any time of the day or night. (Most VAD placements take place during week-
day mornings when the scientists are typically at work already.) Having a large 
team of scientists available to procure samples places less burden on each 
individual and makes it easier to provide 24/7 cover. However, having a team 
that is too large is also problematic. For example, if each scientist only performs 
a few procedures it can be difficult to ensure that samples are dissected 
consistently. A large team also makes it harder for each scientist to build their 
working relationship with the clinical staff in the operating room. This relationship 
is important because the clinical staff need to be confident that the scientist can 
collect the samples without compromising any aspect of the surgery. We have 
found that the system works best at our institution with a team of ~4 scientists. 
Another challenge is obtaining non-failing hearts. Data provided by our local 
organ procurement agency (Kentucky Organ Donor Affiliates) show that thoracic 
organs are donated roughly once per week at the University of Kentucky. Since 
many hearts are not suitable for transplant, it might be possible to obtain non-
failing hearts once every 2 or 3 weeks. In practice, we have collected an average 
of about two per year. The main problem has been that our clinical collaborators 
are not normally involved in organ procurements when the heart is not being 
used for transplant. Thus, we don’t learn about organ procurements until after 
they have occurred. We are trying to improve our performance in this area and 
have recently developed stronger interactions with the organ donation team at 
our institution. We hope that this new development will help us to accelerate the 
rate at which we procure non-failing hearts. 
Item Cost Yearly estimate 
Sample vials  $180 per case  $540 
(~3 cases per year) 
Liquid nitrogen $38 per month $456 
Phone $50 per month $600 
Cryogenic tanks  $5,000 per tank 
(holds ~1600 vials) 
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One of the main interests of our lab is understanding how regional and 
transmural patterns of contraction influence ventricular function. To learn more 
about these effects, we measure the biochemical and contractile properties of 
cells from different parts of the heart. It is not yet clear how these properties are 
distributed, which makes it difficult to know the optimal way to dissect the 
samples. The practical approach that we have taken for left ventricular tissue is 
to separate the free wall into thirds (Fig. 2a). This is probably not a perfect 
solution but it has shown useful results in both rats and humans (9, 14). 
We have also thought about how freezing the samples might influence the 
experimental results. To learn more about these potential effects, we would need 
to perform multiple experiments comparing fresh and previously frozen samples. 
This is difficult for our group because we don’t normally have enough 
experienced scientists on hand to process the samples and to run the 
mechanical experiments at the same time. It is particularly hard to run 
mechanical experiments on tissue obtained from transplants since these 
procedures normally take place outside normal working hours. 
Recommendations 
 
We have gained a great deal of practical experience since we started this 
protocol in 2008. This section lists a few ideas and concepts that groups who are 
considering starting their own protocols may wish to consider. 
 
Develop positive relationships with your IRB and biosafety teams 
 
 We spoke to members of our IRB before we started writing our protocol 
so that we could gain from their experience and advice. We also initiated 
interactions with our biosafety advisors rather than waiting until our labs 
were inspected. This helped us to develop protocols that are good for our 
patients, our institution, and the researchers who perform the 
experiments. 
 
Interact with patients and seek their opinions 
 
 It is important that patients understand how their samples will be used 
and what our research is trying to achieve. We try to meet regularly with 
patients and make sure that they support our goals. The VAD and 
Transplant Support Group at our institution provides an ideal forum for 
these interactions. 
 
Identify key personnel who are responsible for specific tasks 
 
 Rather than taking turns on each aspect of the protocol, we ask key 
personnel to run specific components. For example, a transplant 
coordinator consents each patient who will be listed for a heart transplant, 
a scientist manages the inventory, and a faculty member collates clinical 
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data from the medical records. We have found that this helps to maintain 
consistency and allows team members to specialize in specific areas. 
 
Simplify communication 
 
 We provide a single telephone number that the operating room can call 
when cardiac tissue might become available. This number is associated 
with a single cell phone that the scientists take turns carrying. An 
alternative would be to use a forwarding system (such as Google Voice) 
that sends a call to multiple phones. On balance, our team prefers to use 
a dedicated phone rather than linking their personal cellphones to the 
tissue procurement process. 
 
Do not hoard samples 
 
 Patients do not donate their cardiac tissue so that it can be stored in a 
freezer. Instead, they hope that their samples might help other people 
from having to receive heart transplants or ventricular assist devices. We 
try to share any samples that we do not need for our own experiments 
with other research groups. Our goal is to work together to accelerate 
research focusing on advanced heart failure. 
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